0001161697-23-000129.txt : 20230217 0001161697-23-000129.hdr.sgml : 20230217 20230217170115 ACCESSION NUMBER: 0001161697-23-000129 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harper Molly CENTRAL INDEX KEY: 0001871470 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 23643670 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 4 1 form_4.xml FORM 4 FOR 02-15-2023 X0306 4 2023-02-15 0 0001369568 CATALYST PHARMACEUTICALS, INC. CPRX 0001871470 Harper Molly 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 1 0 0 0 Common Stock, par value $0.001 per share 2023-02-15 4 M 0 4000 A 4000 D Restricted Stock Units 2023-02-15 4 M 0 4000 0 A Common Stock 4000 107000 D Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023. /s/ Molly Harper 2023-02-17